🟢 Kailera Therapeutics Surges 4.1% on Completion of Phase 3 Enrollment for Obesity Drug

Kailera Therapeutics is trading at $11.44, up 4.1%, following a significant company announcement. * On September 30, the company announced the completion of enrollment in its three-trial global Phase 3 KaiNETIC program for ribupatide, an investigational once-weekly dual GLP-1/GIP receptor agonist for obesity treatment. * Topline results from the KaiNETIC program are expected in mid-2028, marking a key milestone in the drug's development. * The company is also scheduled to participate in the Stifel 2026 Virtual Cardiometabolic Forum at 11:30 a.m. EDT.